{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:40:15Z","timestamp":1791492015068,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Symptoms of menopause and the sequelae of gynecologic cancer treatment can be severe in their physical and mental impact on patient quality of life. Survivors of certain gynecologic cancers \u2013 namely, early-stage, low-grade endometrial cancers; epithelial and germ cell ovarian cancers; and early-stage squamous cell cervical, vulvar, and vaginal cancers \u2013 as well as those who have undergone risk-reducing surgery for BRCA or Lynch syndrome mutations may safely use hormone replacement therapy (HRT). Treatment is ideally initiated in patients younger than age 60 or within ten years of menopause. The decision to start treatment should be made on an individualized basis after discussion of risks, benefits, and symptom severity with patients. Data suggest that the safest HRT regimens in this population include low-dose vaginal estrogen for the treatment of vulvovaginal symptoms, or low-dose systemic estrogen for the treatment of vasomotor symptoms, combined with progesterone in patients with an intact uterus. Therapies such as SSRIs\/SNRIs, vaginal moisturizers, pelvic floor physical therapy, and psychosocial counseling should also be considered when appropriate for their effectiveness in managing menopausal symptoms without the potential risk of hormones.<\/jats:p>","DOI":"10.1007\/s11864-025-01298-5","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:45:21Z","timestamp":1741149921000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Updates in Hormone Replacement Therapy for Survivors of Gynecologic Cancers"],"prefix":"10.1007","volume":"26","author":[{"given":"Megan","family":"Gorman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"2","key":"1298_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0378-5122(92)90003-M","volume":"14","author":"SM McKinlay","year":"1992","unstructured":"McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas. 1992;14(2):103\u201315. https:\/\/doi.org\/10.1016\/0378-5122(92)90003-M.","journal-title":"Maturitas"},{"issue":"2","key":"1298_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ygyno.2011.03.012","volume":"122","author":"O Ibeanu","year":"2011","unstructured":"Ibeanu O, Modesitt SC, Ducie J, et al. Hormone replacement therapy in gynecologic cancer survivors: Why not? Gynecol Oncol. 2011;122(2):447\u201354. https:\/\/doi.org\/10.1016\/j.ygyno.2011.03.012.","journal-title":"Gynecol Oncol"},{"key":"1298_CR3","doi-asserted-by":"publisher","unstructured":"Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;2004(4):CD002978. https:\/\/doi.org\/10.1002\/14651858.CD002978.pub2.","DOI":"10.1002\/14651858.CD002978.pub2"},{"key":"1298_CR4","doi-asserted-by":"publisher","unstructured":"Pinkerton JV, Constantine G, Hwang E, et al. Study 3353 Investigators. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: A 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013;20(1):28\u201337. https:\/\/doi.org\/10.1097\/gme.0b013e31826421a8.","DOI":"10.1097\/gme.0b013e31826421a8"},{"key":"1298_CR5","doi-asserted-by":"publisher","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333. https:\/\/doi.org\/10.1001\/jama.288.3.321.","DOI":"10.1001\/jama.288.3.321"},{"key":"1298_CR6","doi-asserted-by":"publisher","unstructured":"Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701\u201312. https:\/\/doi.org\/10.1001\/jama.291.14.1701.","DOI":"10.1001\/jama.291.14.1701"},{"key":"1298_CR7","doi-asserted-by":"publisher","unstructured":"American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202\u201316. https:\/\/doi.org\/10.1097\/01.AOG.0000441353.20693.78.","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"issue":"1","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/01.AOG.0000296714","volume":"111","author":"G Bachmann","year":"2008","unstructured":"Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Obstet Gynecol. 2008;111(1):67\u201376. https:\/\/doi.org\/10.1097\/01.AOG.0000296714.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","volume":"24","author":"CL Loprinzi","year":"2006","unstructured":"Loprinzi CL, Levitt R, Barton D, et al. Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. J Clin Oncol. 2006;24(9):1409\u201314. https:\/\/doi.org\/10.1200\/JCO.2005.04.7324.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2018-01345","volume":"103","author":"SR Davis","year":"2018","unstructured":"Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146\u201354. https:\/\/doi.org\/10.1210\/jc.2018-01345.","journal-title":"J Clin Endocrinol Metab"},{"key":"1298_CR11","doi-asserted-by":"publisher","unstructured":"Warnock JK, Swanson SG, Borel RW, et al. ESTRATEST Clinical Study Group. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause. 2005;12(4):374\u201384. https:\/\/doi.org\/10.1097\/01.GME.0000153933.50860.FD.","DOI":"10.1097\/01.GME.0000153933.50860.FD"},{"issue":"7","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.4065\/mcp.2010.0714","volume":"86","author":"JA Files","year":"2011","unstructured":"Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86(7):673\u201380. https:\/\/doi.org\/10.4065\/mcp.2010.0714.","journal-title":"Mayo Clin Proc"},{"key":"1298_CR13","doi-asserted-by":"publisher","first-page":"1397123","DOI":"10.3389\/fgwh.2024.1397123","volume":"5","author":"D Kissinger","year":"2024","unstructured":"Kissinger D. Hormone replacement therapy perspectives. Front Glob Womens Health. 2024;5:1397123. https:\/\/doi.org\/10.3389\/fgwh.2024.1397123.","journal-title":"Front Glob Womens Health"},{"issue":"3","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","volume":"19","author":"The North American Menopause Society","year":"2012","unstructured":"The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257\u201371. https:\/\/doi.org\/10.1097\/gme.0b013e31824b970a.","journal-title":"Menopause"},{"key":"1298_CR15","doi-asserted-by":"publisher","unstructured":"Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266\u201373. https:\/\/doi.org\/10.1097\/AOG.0000000000005395.","DOI":"10.1097\/AOG.0000000000005395"},{"issue":"13","key":"1298_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2013.278040","volume":"310","author":"JE Manson","year":"2013","unstructured":"Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials. JAMA. 2013;310(13):1353\u201368. https:\/\/doi.org\/10.1001\/jama.2013.278040.","journal-title":"JAMA"},{"key":"1298_CR17","doi-asserted-by":"publisher","unstructured":"Chlebowski RT, Anderson GL, Sarto GE, et al. Continuous combined estrogen plus progestin and endometrial cancer: The Women's Health Initiative randomized trial. J Natl Cancer Inst. 2016;108(3). https:\/\/doi.org\/10.1093\/jnci\/djv350.","DOI":"10.1093\/jnci\/djv350"},{"issue":"30","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.23.01918","volume":"42","author":"RT Chlebowski","year":"2024","unstructured":"Chlebowski RT, Aragaki AK, Pan K, et al. Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women\u2019s Health Initiative randomized trials. J Clin Oncol. 2024;42(30):3537\u201349. https:\/\/doi.org\/10.1200\/JCO.23.01918.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1298_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","volume":"24","author":"RR Barakat","year":"2006","unstructured":"Barakat RR, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(4):587\u201392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1298_CR20","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","volume":"50","author":"SH Shim","year":"2014","unstructured":"Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: A meta-analysis. Eur J Cancer. 2014;50(9):1628\u201337.","journal-title":"Eur J Cancer"},{"key":"1298_CR21","first-page":"CD008830","volume":"5","author":"KA Edey","year":"2018","unstructured":"Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5:CD008830.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"1298_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/01.lgt.0000210128.93392.65","volume":"10","author":"BA McDonnell","year":"2006","unstructured":"McDonnell BA, Twiggs LB. Hormone replacement therapy in endometrial cancer survivors: New perspectives after the Heart and Estrogen Progestin Replacement Study and the Women\u2019s Health Initiative. J Low Genit Tract Dis. 2006;10(2):92\u2013101. https:\/\/doi.org\/10.1097\/01.lgt.0000210128.93392.65.","journal-title":"J Low Genit Tract Dis"},{"issue":"9574","key":"1298_CR23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","volume":"369","author":"V Beral","year":"2007","unstructured":"Beral V, Bull D, Green J, Reeves G, Collaborators MWS. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(07)60534-0.","journal-title":"Lancet"},{"issue":"1","key":"1298_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/13697137.2012.663818","volume":"16","author":"V Koskela-Niska","year":"2013","unstructured":"Koskela-Niska V, Lyytinen H, Riska A, Pukkala E, Ylikorkala O. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy: A nationwide study. Climacteric. 2013;16(1):48\u201353. https:\/\/doi.org\/10.3109\/13697137.2012.663818.","journal-title":"Climacteric"},{"issue":"12","key":"1298_CR25","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/aje\/kwr446","volume":"175","author":"LS M\u00f8rch","year":"2012","unstructured":"M\u00f8rch LS, L\u00f8kkegaard E, Andreasen AH, Kjaer SK, Lidegaard O. Hormone therapy and different ovarian cancers: A national cohort study. Am J Epidemiol. 2012;175(12):1234\u201342. https:\/\/doi.org\/10.1093\/aje\/kwr446.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"1298_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.bjc.6603527","volume":"96","author":"KN Danforth","year":"2007","unstructured":"Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer. 2007;96(1):151\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6603527.","journal-title":"Br J Cancer"},{"issue":"6","key":"1298_CR27","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jnci\/djad035","volume":"115","author":"A Fournier","year":"2023","unstructured":"Fournier A, Cairat M, Severi G, Gunter MJ, Rinaldi S, Dossus L. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J Natl Cancer Inst. 2023;115(6):671\u20139. https:\/\/doi.org\/10.1093\/jnci\/djad035.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1298_CR28","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1002\/ijc.22218","volume":"119","author":"C Mascarenhas","year":"2006","unstructured":"Mascarenhas C, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer. 2006;119(12):2907\u201315.","journal-title":"Int J Cancer"},{"issue":"35","key":"1298_CR29","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","volume":"33","author":"RA Eeles","year":"2015","unstructured":"Eeles RA, et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: Results of the AHT randomized trial. J Clin Oncol. 2015;33(35):4138\u201344.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1298_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ygyno.2015.07.109","volume":"139","author":"D Li","year":"2015","unstructured":"Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. Gynecol Oncol. 2015;139(2):355\u201362.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"1298_CR31","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.3390\/cancers14133090","volume":"14","author":"E Ji","year":"2022","unstructured":"Ji E, Kim K, Lee B, Hwang SO, Lee HJ, Lee K, Lee M, Kim YB. Postoperative hormone replacement therapy and survival in women with ovarian cancer. Cancers (Basel). 2022;14(13):3090. https:\/\/doi.org\/10.3390\/cancers14133090.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1298_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","volume":"23","author":"V Pergialiotis","year":"2016","unstructured":"Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: Systematic review and meta-analysis. Menopause. 2016;23(3):335\u201342. https:\/\/doi.org\/10.1097\/GME.0000000000000508.","journal-title":"Menopause"},{"issue":"5","key":"1298_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/jcm13051443","volume":"13","author":"P Villa","year":"2024","unstructured":"Villa P, Bounous VE, Amar ID, Bernardini F, Giorgi M, Attianese D, Ferrero A, D\u2019Oria M, Scambia G. Hormone replacement therapy in post-menopause hormone-dependent gynecological cancer patients: A narrative review. J Clin Med. 2024;13(5):1443. https:\/\/doi.org\/10.3390\/jcm13051443.","journal-title":"J Clin Med"},{"issue":"2","key":"1298_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","volume":"26","author":"E Ploch","year":"1987","unstructured":"Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26(2):169\u201377.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1298_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13697137.2020.1826426","volume":"24","author":"V Vargiu","year":"2021","unstructured":"Vargiu V, Amar ID, Rosati A, Dinoi G, Turco LC, Capozzi VA, Scambia G, Villa P. Hormone replacement therapy and cervical cancer: A systematic review of the literature. Climacteric. 2021;24(2):120\u20137. https:\/\/doi.org\/10.1080\/13697137.2020.1826426.","journal-title":"Climacteric"},{"issue":"3","key":"1298_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/20533691211028518","volume":"27","author":"A Richardson","year":"2021","unstructured":"Richardson A, Watson L, Persic M, Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post Reprod Health. 2021;27(3):167\u201373. https:\/\/doi.org\/10.1177\/20533691211028518.","journal-title":"Post Reprod Health"},{"key":"1298_CR37","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.maturitas.2016.07.018","volume":"92","author":"CL Kuhle","year":"2016","unstructured":"Kuhle CL, Kapoor E, Sood R, Thielen JM, Jatoi A, Faubion SS. Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas. 2016;92:86\u201396. https:\/\/doi.org\/10.1016\/j.maturitas.2016.07.018.","journal-title":"Maturitas"},{"key":"1298_CR38","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins \u2013 Gynecology. ACOG practice bulletin no. 182: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol. 2017;130(3):e110\u201326.","DOI":"10.1097\/AOG.0000000000002296"},{"issue":"8","key":"1298_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","volume":"4","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol. 2018;4(8):1059\u201365.","journal-title":"JAMA Oncol"},{"key":"1298_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejca.2021.02.007","volume":"148","author":"R Michaelson-Cohen","year":"2021","unstructured":"Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer. 2021;148:95\u2013102.","journal-title":"Eur J Cancer"},{"issue":"31","key":"1298_CR41","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"TR Rebbeck","year":"2005","unstructured":"Rebbeck TR, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol. 2005;23(31):7804\u201310.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1298_CR42","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/GME.0000000000000126","volume":"21","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, et al. Hormone therapy in oophorectomized BRCA1\/2 mutation carriers. Menopause. 2014;21(7):763\u20138.","journal-title":"Menopause"},{"issue":"1","key":"1298_CR43","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","volume":"153","author":"S Gordhandas","year":"2019","unstructured":"Gordhandas S, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations: A systematic review of risks and benefits. Gynecol Oncol. 2019;153(1):192\u2013200.","journal-title":"Gynecol Oncol"},{"key":"1298_CR44","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins \u2013 Gynecology. ACOG practice bulletin no. 147: Lynch syndrome. Obstet Gynecol. 2014;124(5):1042\u201354.","DOI":"10.1097\/01.AOG.0000456325.50739.72"},{"key":"1298_CR45","doi-asserted-by":"publisher","unstructured":"\u201cThe 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767\u2013794. https:\/\/doi.org\/10.1097\/GME.0000000000002028. PMID: 35797481.","DOI":"10.1097\/GME.0000000000002028"},{"key":"1298_CR46","doi-asserted-by":"publisher","unstructured":"Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, Olivera CK, Abed H, Balk EM, Murphy M; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147\u20131156. https:\/\/doi.org\/10.1097\/AOG.0000000000000526.","DOI":"10.1097\/AOG.0000000000000526"},{"issue":"2","key":"1298_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","volume":"222","author":"KK Crean-Tate","year":"2020","unstructured":"Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: A focus on vaginal hormonal therapy. Am J Obstet Gynecol. 2020;222(2):103\u201313. https:\/\/doi.org\/10.1016\/j.ajog.2019.08.043.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1298_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/GCO.0000000000000238","volume":"28","author":"RL O'Donnell","year":"2016","unstructured":"O\u2019Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynecological malignancy. Curr Opin Obstet Gynecol. 2016;28(1):32\u201341. https:\/\/doi.org\/10.1097\/GCO.0000000000000238.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1298_CR49","doi-asserted-by":"publisher","unstructured":"Palaia I, Caruso G, Di Donato V, Turetta C, Savarese A, Perniola G, Gallo R, Giannini A, Salutari V, Bogani G, Tomao F, Giannarelli D, Gentile G, Musella A, Muzii L, Pignata S; MITO group. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: A MITO group survey. J Gynecol Oncol. 2024;35(3):e70. https:\/\/doi.org\/10.3802\/jgo.2024.35.e70.","DOI":"10.3802\/jgo.2024.35.e70"},{"issue":"3","key":"1298_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/GRF.0000000000000381","volume":"61","author":"EMBB Kapoor","year":"2018","unstructured":"Kapoor EMBB, Benrubi DM, Faubion SS. Menopausal hormone therapy in gynecologic cancer survivors: A review of the evidence and practice recommendations. Clin Obstet Gynecol. 2018;61(3):488\u201395. https:\/\/doi.org\/10.1097\/GRF.0000000000000381.","journal-title":"Clin Obstet Gynecol"},{"issue":"2","key":"1298_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2020.01.035","volume":"157","author":"AK Sinno","year":"2020","unstructured":"Sinno AK, Pinkerton J, Febbraro T, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020;157(2):303\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.035.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1298_CR52","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/AOG.0000000000005506","volume":"143","author":"K Robison","year":"2024","unstructured":"Robison K, Kulkarni A, Dizon DS. Sexual Health in Women Affected by Gynecologic or Breast Cancer. Obstet Gynecol. 2024;143(4):499\u2013514. https:\/\/doi.org\/10.1097\/AOG.0000000000005506.","journal-title":"Obstet Gynecol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01298-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T22:04:46Z","timestamp":1742335486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01298-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}